GSK’s lung cancer therapy gains EMA PRIME designation
The EMA's decision is based on the early clinical outcomes from the ARTEMIS-001 study.
Syngene Thematic ADC WP
ADCs breach barriers to become mainstream cancer treatment
Daiichi Sankyo secures breakthrough designation for NSCLC treatment
Cell and gene therapy companies must demonstrate strong value proposition for investment
Allink Biotherapeutics secures funding to advance ADC pipeline
Adcendo raises $135m as ADC funding frenzy continues
Samsung Biologics inks $668m manufacturing deal with European pharma
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
